OTCMKTS:AOLS - Aeolus Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0030 0.00 (0.00 %) (As of 11/12/2018 04:00 PM ET)Previous Close$0.0040Today's Range$0.0030 - $0.003552-Week Range$0.0010 - $0.11Volume8,000 shsAverage Volume27,614 shsMarket Capitalization$460,000.00P/E RatioN/ADividend YieldN/ABeta2.24 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Receive AOLS News and Ratings via Email Sign-up to receive the latest news and ratings for AOLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AOLS Previous Symbol CUSIPN/A Webwww.aeoluspharma.com Phone949-481-9825 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.08 million Price / Sales0.22 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares152,090,000Market Cap$460,000.00 OptionableNot Optionable Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions What is Aeolus Pharmaceuticals' stock symbol? Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS." How were Aeolus Pharmaceuticals' earnings last quarter? Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) posted its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.01 million during the quarter. View Aeolus Pharmaceuticals' Earnings History. Has Aeolus Pharmaceuticals been receiving favorable news coverage? News stories about AOLS stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aeolus Pharmaceuticals earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the next few days. Who are some of Aeolus Pharmaceuticals' key competitors? Some companies that are related to Aeolus Pharmaceuticals include Aytu Bioscience (AYTU), Cotinga Pharmaceuticals (COTQF), Affymax (AFFY), Spotlight Innovation (STLT), Myrexis (MYRX), Tetralogic Pharmaceuticals (TLOG), Targeted Medical Pharma (TRGM), HST Global (HSTC), American Oriental Bioengineering (AOBI), Orexigen Therapeutics (OREXQ), Poniard Pharmaceuticals (PARD), Inspyr Therapeutics (NSPX), Pivotal Therapeutics (PVTTF), Epirus Biopharmaceuticals (EPRSQ) and Advanced Accelerator Application (AAAP). Who are Aeolus Pharmaceuticals' key executives? Aeolus Pharmaceuticals' management team includes the folowing people: Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 49)Mr. John L. Mcmanus, Chief Exec. Officer and Pres (Age 54)Mr. Christopher Stanley, VP of Operations How do I buy shares of Aeolus Pharmaceuticals? Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aeolus Pharmaceuticals' stock price today? One share of AOLS stock can currently be purchased for approximately $0.0030. How big of a company is Aeolus Pharmaceuticals? Aeolus Pharmaceuticals has a market capitalization of $460,000.00 and generates $2.08 million in revenue each year. What is Aeolus Pharmaceuticals' official website? The official website for Aeolus Pharmaceuticals is http://www.aeoluspharma.com. How can I contact Aeolus Pharmaceuticals? Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected] MarketBeat Community Rating for Aeolus Pharmaceuticals (OTCMKTS AOLS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 47 (Vote Outperform)Underperform Votes: 67 (Vote Underperform)Total Votes: 114MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/12/2018 by MarketBeat.com StaffFeatured Article: What Are Treasury Bonds?